Interventional Cardiology Market Forecast
Global Interventional Cardiology Market held a value of USD 15,130.75 Million in 2018 and is expected to register a CAGR of 7.25% during the assessment period of 2019 to 2025.
Interventional Cardiology Market Synopsis
Interventional cardiology deals with the catheter-based treatment of heart diseases. Scrutinizing all the global territories, it has been noticed that there is a huge rise in the number of cardiac diseases. This can be attributed to the change in lifestyle, leading to lifestyle diseases. Each year cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).
In addition to that, the rise in the number of clinical trials of devices for use in interventional cardiology procedures is set to propel the growth of the market. For instance, in August 2018, B. Braun Melsungen AG announced that its drug-coated balloon ‘SeQuent Please’ for percutaneous transluminal coronary angioplasty showed positive results in the BASKET-SMALL 2 clinical trial. Moreover, the trend of bioresorbable stents going to contribute substantially to the growth of the market. For instance, in February 2019, Biotronik was granted approval from the FDA for its a drug-eluting stent system which is ultrathin and bioabsorbable for the treatment of patients with coronary artery disease.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8735
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held maximum share in the base year 2018, owing to the high incidence rates of cardiac disorders and strategic activities by major players in countries such as the US. The interventional cardiology market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European interventional cardiology market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The European market for interventional cardiology is expected to hold a substantial share owing to the increase in the number of cardiac disorder cases. For instance, in 2016, there were 66,076 deaths due to coronary heart diseases in the UK, which was the third-highest cause of death in that particular year. The interventional cardiology market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The interventional cardiology market in this region is anticipated to be the fastest-growing during the forecast period due to the increasing uptake and adoption rate of newer treatment options by patients as well as medical professionals. The increasing patient pool and mortality rate due to cardiac diseases in these countries also fuel the market growth. For instance, in 2017, ischemic heart disease was the second-highest cause for death in Japan. The interventional cardiology market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Interventional Cardiology Market has been segmented based on Type, and End User.
The market, based on type, has been segmented into stents, percutaneous transluminal coronary angioplasty (PTCA) catheters, plaque modification devices, coronary guidewires, and accessories. The market, based on stents, has been further divided into drug-eluting stents, bare-metal stents, and bioresorbable vascular scaffolds. The stents segment held a major share in 2018 owing to the increased number of product launches by key players in the current years. This segment is also expected to be the fastest-growing segment during the forecast period due to the increasing prevalence of coronary artery disease, and continued innovations by players. The market, based on PTCA catheters, has been segmented into balloon catheters, and guiding catheters.
The Global Interventional Cardiology Market has been segmented, based on end-user, into hospitals, cardiac catheterization laboratories, ambulatory surgical centers, and others. In 2018, the hospital's segment held the majority share of the market owing to the increasing number of patient admissions due to coronary diseases. The cardiac catheterization laboratory segment is projected to be the fastest-growing segment owing to the increasing preference of cath labs by medical professionals.
Key Players
Some of the Key Players in the Global Interventional Cardiology Market are ABIOMED (US), Abbott (US), ACIST Medical Systems, Inc. (the US), B. Braun Melsungen AG (Germany), BD (US), Biosense Webster, Inc (US), Biotronik SE & Co. KG (Germany), Boston Scientific Corporation (US), Cardinal Health (US), Cook Medical (US), Edwards Lifesciences Corporation (US), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Life Vascular Devices Biotech S.L. (Spain), Medtronic (Ireland), Merit Medical Systems, Inc (US), Terumo Corporation (Japan), and W. L. Gore & Associates, Inc. (US).
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/interventional-cardiology-market-8735
Market HighlightsAccording to MRFR analysis, the Global Interventional Cardiology Market is expected to register a CAGR of 7.25% from 2019 to 2025 and held a value of USD 15,130.75 Million in 2018.The interventional cardiology market is driven by several factors, such as technological advancements in interventional cardiac devices, rising prevalence of cardiac diseases, increasing preference for minimally invasive procedures, and increasing geriatric population.
The Americas held maximum share in the base year 2018, owing to the high incidence rates of cardiac disorders and strategic activities by major players in countries such as the US.
The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The interventional cardiology market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.SegmentationThe Global Interventional Cardiology Market has been segmented based on Type, and End User.The market, based on type, has been segmented into stents, percutaneous transluminal coronary angioplasty (PTCA) catheters, plaque modification devices, coronary guidewires, and accessories.
The stents segment held a major share in 2018 owing to the increased number of product launches by key players in the current years.
This segment is also expected to be the fastest-growing segment during the forecast period due to the increasing prevalence of coronary artery disease, and continued innovations by players.
Autoinjectors are easy-to-handle and cost-effective medical devices that can be used by patients, caregivers, and even untrained personnel to deliver a dose of a particular drug.
Autoinjectors are used by patients to manage autoimmune diseases and chronic diseases.
They are used for a wide range of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors marketRheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues.
It causes joints to swell and can result in pain, stiffness, and progressive loss of function.
According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia.What Drives the Market?1.
Growing prevalence of targeted therapies2.
The Global Remote Patient Monitoring Devices Market Size is anticipated to reach over USD 1,882.75 Million by 2025 according to a new research published by Polaris Market Research.
Growing usage of smartphones and increasing the expansion of the smartphone applications that are linked to the monitoring devices further helps in transmitting and recording person’s health-related data to the healthcare suppliers or specialists.
However, the high cost associated with this device, stringent reimbursement guidelines and issues correlated with the government regulations are some of the factors anticipated to hinder the global market growth.
The global Remote Patient Monitoring Devices Market is segmented on the basis of product type, application, end user, and geography.
On the basis of product type, the global Remote Patient Monitoring Devices Market is segmented into Heart Rate Monitors, Heart Monitors, Blood Pressure Monitors, Sleep Apnea Monitors, Breath Monitors, Weight Monitors, Blood Glucose Monitors, Infusion Pumps, and Body Temperature Monitors.
In 2017, cardiovascular disease treatment is estimated to dominate the market growth majorly owing to the increasing incidences of cardiovascular diseases.
